| Name | Title | Contact Details |
|---|
C4 Therapeutics is pioneering a new class of drugs. C4`s technology platform produces small molecule drugs that harness machinery already present in cells to selectively target disease-relevant proteins for degradation. Our approach has the potential to address a broad range of diseases including cancer, infectious disease, and autoimmune disorders.
Kira Biotech is an emerging Australian biotechnology company developing novel immunomodulatory compounds for the treatment of immune system disorders.
Opus Genetics is a groundbreaking gene therapy company for inherited retinal diseases with a unique model and purpose. Backed by Foundation Fighting Blindness`s venture arm, the RD Fund, Opus combines unparalleled insight and commitment to patient need with wholly owned programs in numerous orphan retinal diseases.
Previously Mr. Lerner has served as Vice President of Engineering and Technology for both Image Sensing Systems, Inc. and Telex Communications, Inc.
HealthTech Holdings Inc. is a health information technology holding company that owns Healthcare Management Systems, MEDHOST and Sentry Healthcare Services.